Home / Companies / News /  FIPB refers Rs4,197 crore Glenmark, Aurobindo Pharma proposals to CCEA

New Delhi: The finance ministry on Thursday referred the foreign investment proposals worth 4,187 crore in pharma firms—Glenmark Pharmaceuticals and Aurobindo Pharma—to the cabinet committee on economic affairs (CCEA).

The foreign investment promotion board (FIPB) has sent the proposal of Mumbai-based Glenmark Pharmaceuticals to the CCEA, headed by Prime Minister Narendra Modi, to raise the cap of foreign institutional investor (FII) holding to 49% from present 35.07%, an official statement said. The move, if cleared would facilitate the drug firm to bring in 2,022 crore of foreign funds into the country.

Besides, FIPB has also sent the proposal of Hyderabad-based Aurobindo Pharma for bringing in 2,165 crore foreign investment by qualified institutional buyers to the CCEA.

“The following two proposals have been recommended for consideration of the CCEA, as the investment involved in each of the proposal is above 1,200 crore," the statement said.

Glenmark Pharmaceuticals, which has significant presence in branded generics markets across emerging economies including India, employs over 10,400 people in over 80 countries.

Aurobindo Pharma has presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

Last month, the CCEA had allowed drug maker Lupin to raise the FII cap to 49%, a move that would facilitate an inflow of 6,099 crore.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Edit Profile
Get alerts on WhatsApp
My ReadsRedeem a Gift CardLogout